Abstract
Polyoxometalates (POMs) have shown promising antitumor activities attributed to their virtue of incomparable structural versatility and interesting redox properties. However, the clinical application of POM drugs is limited by their poor stability and low anticancer specificity. To overcome these shortcomings, a multifunctional platform based on POMs (the tetrabutylammonium salts of [PW12O40]3−, [V10O28H3]3− and [Mo6O19]2−) and MIL-100 (Fe) was successfully developed for combined chemical and chemodynamic therapy, ultimately inducing cancer cell apoptosis. The prepared POMs@MIL-100 (Fe) composites showed great efficiency in killing MCF-7 and 4T1 cells while with a low toxicity to normal MCF-10A and C2C12 cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
